Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bjh.17256 http://scihub22266oqcxt.onion/10.1111/bjh.17256 33249579!ä!33249579 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Br+J+Haematol 2021 ; 193 (6): 1034-1043 Nephropedia Template TP {{tp|p=33249579|t=2021. Controversies in the use of new bone-modifying therapies in multiple myeloma |pdf=|usr=}}{{33249579}} gab.com Text Controversies in the use of new bone-modifying therapies in multiple myeloma JO: Br J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=33249579 #FOAvip Bone-modifying therapies are essential in the treatment of patients with multiple myeloma. Zoledronic acid is preferred over other bisphosphonates due to its superiority in reducing the incidence of skeletal-related events and improving survival. The anti-receptor activator of nuclear factor-kappaBeta ligand (RANKL)-targeted agent denosumab has shown its non-inferiority compared to bisphosphonates in preventing skeletal-related events among newly diagnosed patients with myeloma bone disease. Denosumab may confer a survival benefit in patients eligible for autologous transplantation. Denosumab may present a safer profile for patients with renal impairment. Discontinuation of bone-directed therapies can be considered for patients with deep responses and after an adequate time period on treatment; however, a rebound effect may become evident especially in the case of denosumab. Three-monthly infusions of zoledronic acid or at-home denosumab administration should be considered during the coronavirus disease 2019 (COVID-19) pandemic. Measures to prevent hypocalcaemia, renal toxicity and osteonecrosis of the jaw are important for all bone-modifying agents. Twit Text FOAVip Controversies in the use of new bone-modifying therapies in multiple myeloma ????Br J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=33249579 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33249579 #FOAvip English Wikipedia <ref>{{Cite pmid|33249579}}</ref> Controversies in the use of new bone-modifying therapies in multiple myeloma #MMPMID33249579 Terpos E; Ntanasis-Stathopoulos I Br J Haematol 2021[Jun]; 193 (6): 1034-1043 PMID33249579show ga Bone-modifying therapies are essential in the treatment of patients with multiple myeloma. Zoledronic acid is preferred over other bisphosphonates due to its superiority in reducing the incidence of skeletal-related events and improving survival. The anti-receptor activator of nuclear factor-kappaBeta ligand (RANKL)-targeted agent denosumab has shown its non-inferiority compared to bisphosphonates in preventing skeletal-related events among newly diagnosed patients with myeloma bone disease. Denosumab may confer a survival benefit in patients eligible for autologous transplantation. Denosumab may present a safer profile for patients with renal impairment. Discontinuation of bone-directed therapies can be considered for patients with deep responses and after an adequate time period on treatment; however, a rebound effect may become evident especially in the case of denosumab. Three-monthly infusions of zoledronic acid or at-home denosumab administration should be considered during the coronavirus disease 2019 (COVID-19) pandemic. Measures to prevent hypocalcaemia, renal toxicity and osteonecrosis of the jaw are important for all bone-modifying agents. |Bone Density Conservation Agents/*adverse effects[MESH] |COVID-19/complications[MESH] |Denosumab/*adverse effects/therapeutic use[MESH] |Diphosphonates/*adverse effects/therapeutic use[MESH] |Humans[MESH] |Hypercalcemia/complications/drug therapy[MESH] |Multiple Myeloma/complications/*drug therapy[MESH] |Osteolysis/complications/drug therapy[MESH] |Receptor Activator of Nuclear Factor-kappa B/*antagonists & inhibitors/metabolism[MESH] |Renal Insufficiency/complications/drug therapy[MESH]Controversies in the use of new bone-modifying therapies in multiple m(epmc).pdf DeepDyve Pubget Overpricing